Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899002 | 1.00 | MEN1 (0.41) | MEN1KMT2APOLBAKT1NPC1 | |
| SCHEMBL30668100 | 0.79 | CTSL (0.38) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL26684141 | 0.79 | CTSL (0.38) | MEN1KMT2APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL3647435 | 0.75 | PRNP (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3647436 | 0.75 | PRNP (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4841820 | 0.74 | KDM4E (0.46) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL31204160 | 0.74 | CES2 (0.50) | KMT2APOLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4841809 | 0.74 | KDM4E (0.46) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL8778837 | 0.74 | CES2 (0.50) | KMT2APOLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1314837 | 0.74 | CES2 (0.50) | KMT2APOLBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376089-A1 | 3-HYDROXY-5-(ISOXAZOL-5-YL) PYRIDINE FORMYLGLYCINE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-116535399-A | 3-hydroxy-5- (isoxazol-5-yl) pyridine formyl glycine compound, preparation method, pharmaceutical composition and application | 中国药科大学 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023142214-A1 | 3-HYDROXY-5-(ISOXAZOL-5-YL) PYRIDINE FORMYLGLYCINE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 中国药科大学 | 2023-08-03 | — | — | WO | disclosed |
| EP-2621920-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | Bristol-Myers Squibb Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20120095011-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| WO-2012044531-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011039276-A1 | OXATHIAZINYL(HET)ARYLSULFONYLUREAS, PROCESSES AND INTERMEDIATES FOR PREPARATION THEREOF AND USE THEREOF AS CROP PROTECTION AGENTS AND CROP GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2011-04-07 | — | — | WO | disclosed |
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090131463-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | disclosed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| EP-1931661-B1 | ISOXAZOLO DERIVATIVES AS GABA A ALPHA5 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-19 | — | — | EP | disclosed |
| CN-101263139-A | Isoxazolo derivatives as GABA A alpha5 inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-09-10 | — | — | CN | disclosed |
| EP-1931661-A1 | ISOXAZOLO DERIVATIVES AS GABA A ALPHA5 INVERSE AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039389-A1 | ISOXAZOLO DERIVATIVES AS GABA A ALPHA5 INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
| CN-1289486-C | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) | ASTRAZENECA AB (SE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1617858-A | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | CN | disclosed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131463-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | MEN1 789/4885KMT2A 3048/4885POLB 4749/4885 |
| US-20120245176-A1 | NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, BAZ2A | MEN1 3660/4885KMT2A 548/4885POLB 2820/4885 |
| US-20240376089-A1 | 3-HYDROXY-5-(ISOXAZOL-5-YL) PYRIDINE FORMYLGLYCINE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | HIF1AN, HIF1A, EGLN3 | MEN1 4609/4885KMT2A 946/4885POLB 3421/4885 |
| US-20070066668-A1 | Isoxazolo derivatives | GABRA5, GABRA4, GABRA1 | MEN1 4745/4885KMT2A 2468/4885POLB 3437/4885 |
| US-20120095011-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | MEN1 789/4885KMT2A 3048/4885POLB 4749/4885 |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | IGF1R, IGFBP1, INSR | MEN1 1458/4885KMT2A 3908/4885POLB 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.